European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.
After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial.
Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.
US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy for patients with haemophilia B, which could see an end to patients needing constant inject
